High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada

Ilan S Schwartz; Daniel Z P Friedman; Lori Zapernick; Tanis C Dingle; Nelson Lee; Wendy Sligl; Nathan Zelyas; Stephanie W Smith

doi:10.1093/cid/ciaa007

High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada

Clin Infect Dis. 2020 Oct 23;71(7):1760-1763. doi: 10.1093/cid/ciaa007.

Authors

Ilan S Schwartz¹, Daniel Z P Friedman¹, Lori Zapernick¹, Tanis C Dingle², Nelson Lee¹, Wendy Sligl^{1

3}, Nathan Zelyas², Stephanie W Smith¹

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Alberta, Canada.
² Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta and Alberta Public Laboratories, Alberta Health Services, Alberta, Canada.
³ Department of Critical Care Medicine, University of Alberta, Alberta, Canada.

PMID: 31905235
DOI: 10.1093/cid/ciaa007

Abstract

From 2014-2019, invasive pulmonary aspergillosis complicated 7.2% (0-23.1% in different influenza seasons) of cases of influenza-associated respiratory failure in Edmonton, Alberta. Disease outcomes ranged from survival without therapy to death despite antifungals. Clinician vigilance, longitudinal local surveillance, and refined criteria to identify patients requiring therapy are needed.

Keywords: Aspergillus; aspergillosis; emerging infections; influenza; intensive care.

MeSH terms

Alberta / epidemiology
Antifungal Agents / therapeutic use
Humans
Influenza, Human* / complications
Influenza, Human* / drug therapy
Influenza, Human* / epidemiology
Invasive Pulmonary Aspergillosis* / diagnosis
Invasive Pulmonary Aspergillosis* / drug therapy
Invasive Pulmonary Aspergillosis* / epidemiology
Pulmonary Aspergillosis*
Retrospective Studies

Substances

Antifungal Agents